Navigation Links
Drug brings relief for many IBS patients who experience constipation
Date:5/18/2008

SAN DIEGO, Calif. Many patients may soon find relief from the bloating, cramping, abdominal pain and constipation associated with irritable bowel syndrome, or IBS.

Lubiprostone, known by the brand name AMITIZA, was just approved by the U.S. Food and Drug Administration for use in women with IBS plus constipation, thanks in part to University of Michigan Health System research that demonstrated the safety and efficacy of the drug for treatment of IBS-C.

Led by U-M gastroenterologist William D. Chey, M.D., the studies show that lubiprostone significantly improves all of the symptoms associated with IBS-C in many women.

Results from these studies will be presented on May 18 and May 19 at Digestive Diseases Week in San Diego.

We found that individuals who were treated with AMITIZA were nearly twice as likely to experience improvement in their IBS symptoms compared to individuals who were treated with placebo," says Chey, director of the Gastrointestinal Physiology Laboratory and professor of internal medicine at the U-M Medical School. Right now, it is the only FDA-approved treatment available that addresses the entire clinical spectrum of symptoms related to IBS-C.

IBS, an often painful disorder of the lower intestine, affects between 10 to 15 percent of the U.S. population.

While IBS is the second-leading cause of work absenteeism behind the common cold, Chey says fewer than half of patients with IBS seek medical treatment. And, he says, most over-the-counter medicines commonly used to treat symptoms fiber, laxatives and stool stimulants dont address the bloating and pain associated with IBS.

Most patients with IBS tend to fall into two categories: IBS-C or IBS with diarrhea. IBS-C is more common among older adults, while IBS-D tends to be seen more in younger patients.

Since the majority of patients with IBS are women, studies involving IBS tend to be made up of predominately female participants more than 80 percent in most cases, Chey estimates.

Although AMITIZA is only approved for use in women with IBS-C, it doesnt mean that the drug doesnt work for men. Unfortunately, we just havent had enough men represented in these studies to make a firm decision on treatment using this drug, notes Chey.

The supplemental New Drug Application for AMITIZA which also is approved by the FDA for treatment of chronic idiopathic constipation was based on two phase III, multi-center trials involving 1,154 participants. These trials compared lubiprostone versus a placebo during the course of 12 weeks. Each participant kept an electronic diary to report weekly outcomes of IBS-C symptoms.

After one week, 20 percent of the lubiprostone participants reported moderate to significant relief of symptoms. By week four, 32 percent said they experienced relief of global IBS-C symptoms abdominal pain, bloating, constipation severity and straining during bowel movements. Lubiprostone also improved stool consistency.

Additionally, Chey will present findings at DDW from a follow-on study related to the two phase III trials. This 48-week study looked at the efficacy and safety of lubiprostone. Many of its 476 participants also took part in the phase III trials. For this study, however, participants all received lubiprostone; no placebos were given.

The study found that lubiprostone is effective and well tolerated in adults with IBS-C for up to one year. The spectrum of symptoms that constitute IBS-C, including abdominal pain and discomfort, bloating and constipation-related complaints, significantly improved during the 48-week treatment period. The most common treatment-related adverse events among the study groups were nausea and diarrhea.


'/>"/>

Contact: Krista Hopson
khopson@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. New drug combination brings 1-2 punch against acute leukemia
2. Adding ultrasound screening to mammography brings benefits, risks
3. BIOCOM Purchasing Group Brings in Four New Contracts
4. Photos: New Kind of Health Care Reform Brings Five-Star Hospitality to Hospital Care
5. New Web Community Brings Together Parents of Visually Impaired Children
6. AgeLab Director Brings Wisdom to Aging Brains
7. Touchstone Energy Open Brings Future PGA Stars, Tourists to Eastern N.C.
8. Spring Weather Brings Flea Season
9. OrthoSynetics(TM) Brings Ad Production Home to New Orleans
10. National Walk for Epilepsy Brings People and Celebrities Together for Epilepsy
11. Dr. Rovenia Brock Brings Secrets of Living Healthy to Susan G. Komen for the Cure(R)s Circle of Promise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... ... manicurist from Greet, S.C., wants to offer people a new way to care for their ... feet, so I know the importance of proper foot care," he said. "In order to ... , The FOOT-TRAN SYSTEM enables a user to clean and exfoliate the bottoms of his ...
(Date:3/30/2017)... ... March 30, 2017 , ... This morning, more than 275 ... their support for an independent Vaccine Safety Commission. Five of the signers of ... will hold a press conference at 9:00 AM Friday, March 31 at ...
(Date:3/29/2017)... ... ... In the United States alone, up to 36% of primary brain tumors ... brain tumors(3). Though most meningiomas are benign, metastatic brain tumors are known to grow ... options, the San Diego Gamma Knife Center offers a precision-medicine based solution ...
(Date:3/29/2017)... ... ... Grass pollen is the main cause of hay fever in the United States, with an ... runs from May to July each year; with the worst time for sufferers being June ... balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in ...
(Date:3/29/2017)... ... 2017 , ... Sublime Naturals and its founder, Kathy Heshelow, are big fans ... been used for thousands of years. , "The West has caught on, and has ... How to Use it For Your Wellness. Overcome Inflammation, Enemy of the Body. " ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets has ... report to their offering. ... The global gas chromatograph market to grow at ... The report, Global Gas Chromatograph Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:3/29/2017)... EAST HANOVER, N.J. , March 29, 2017 ... and Drug Administration (FDA) has accepted the company,s ... review for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen ... refractory (r/r) pediatric and young adult patients with ... first BLA submission by Novartis for a CAR-T. ...
(Date:3/29/2017)... 2017 Research and Markets has announced the addition ... at Proton Therapy Centers & Forecast" report to their offering. ... The South Korean Proton Therapy ... size in 2016. The Untapped Proton Therapy Market for South ... 2016. Proton Therapy plays an important role in delivering ...
Breaking Medicine Technology: